Skip to content
  • About
  • Team
  • Clinical Studies
  • Investing
  • Press
  • Contact
Menu
  • About
  • Team
  • Clinical Studies
  • Investing
  • Press
  • Contact
  • About
  • Team
  • Clinical Studies
  • Investing
  • Press
  • Contact
Menu
  • About
  • Team
  • Clinical Studies
  • Investing
  • Press
  • Contact

The Real World Evidence revolution.

Our aim is to focus on cutting edge pragmatic Real-World Evidence (RWE) Studies to generate clinically meaningful data and physician experience faster, unlocking the true potential of these transformational therapies sooner.

We believe it’s the best way to ensure rapid, safe and appropriate access to reimbursed psychedelic medicines.

Learn more

*Timeline to develop and trial KRN-101 to address cancer-related anxiety & depression.

"These are not studies driven by drug development companies. These are studies driven by clinicians to help patients."
Graeme Mcfarlane
Graeme McfarlaneChief Commercial Officer

Driving positive change.

Psychedelic based medicines will change the way mental health is treated, and as a result, we believe the human experience as a whole will improve.

Leading academics are demonstrating success with psychedelic medicines as therapy for treatment-resistant depression, anxiety, drug addiction and much more.

RWE Studies explained
The human brain on psychedelics
The persistence of homological scaffolds - Results from fMRI networks
Placebo
Psilocybin
Read more >>

FDA Breakthrough Designation

FDA has granted three breakthrough therapy designations. One for MDMA and two psilocybin.

Legally Accepted Therapeutic Use

September 2020, Court approved legal access of Psilocybin therapy for cancer related anxiety – BC, Canada

Continued Sucess for Cancer Related Distress

80% of cancer patients showed major reductions in psychological distress, for up to seven months after only a single-dose administration.

Read more >>

Let us tell you more.

We will email you to start the conversation.

Portable, scalable strategy for revenue growth.

Albert Labs is a catalyst leading a collaboration with academic institutions, hospital networks and existing reimbursement mechanisms.

  • Leveraging existing clinic & research infrastructure.
  • Academic partnerships drive next gen psychedelic R&D.
  • Preidenitfied, accessible patient pools.
  • Proprietary Real World Data to gain early reimbursement.
  • In-house lab results in formulation & delivery IP.

Alberts Labs’ mission to ensure accelerated access to safe and effective psychedelic-assisted therapy for patients with urgent, unmet needs.

Learn more

Real World Evidence for patient acquisition.

Science and continuity for patients in need. Beginning with cancer related distress & existential crisis, we plan to initiate our first Real World Evidence studies across the UK and Europe.

1) 1000 Patient Cohort

Develop safe natural psilocybin therapeutics for cancer related anxiety & depression.

2) Expand Patient Cohort

Increase to multi-centre cancer hospitals with an international scope. Data collection and publishing.

3) Broaden to other mental health conditions

Further increase to international centres. Revised protocols and apply for specials medicine registration.

4) Global Growth

Continue to grow the global market access team. Potential to identify signals for a joint RCT study.

Psychedelic based psychotherapy

Modern science is now thriving to understand the neuro-chemical interactions and medicinal benefits of these substances in controlled, quantifiable clinical settings. With established research continuing to show safe physiological and psychological responses to these compounds. Now is the time to explore the extraordinary therapeutic potential on larger patient cohorts and in the real-world setting.  

Learn more
Clinical Trials

Vs.

Real World Evidence

FDA Breakthrough designation

In October, the Food and Drug Administration took the extraordinary step of granting psilocybin therapy for depression a “breakthrough therapy” designation. That means the treatment has demonstrated such potential that the FDA has decided to expedite its development and review process. It’s a sign of how far the research and the public perception of psychedelics have come.

Psilocybin based medicines

These are natural plants that can help you with cancer-related, depression, anxiety, thanatophobia. Psilocybin is a naturally occurring psychedelic compound found in over 180 species of mushrooms. The effect of psilocybin is due to its effects on serotonin receptors in the brain. The active compound with in psilocybin Tryptamine chemically related to the amino acid tryptophan, and is structurally similar to the neurotransmitter serotonin.

Proven safety

Psilocybin also has strong safety data based on studies conducted before prohibition, and so the FDA has allowed a small number of small clinical trials to move forward.

Continued clinical sucess

From the 2000’s psilocybin research has begun 

– November 30, 2016

1. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.

Stephen Ross, Anthony Bossis, Jeffrey Guss, Gabrielle Agin-Liebes, Tara Malone, Barry Cohen, Sarah E Mennenga, Alexander Belser, Krystallia Kalliontzi, James Babb, Zhe Su, Patricia Corby and Brian L Schmidt.

– November 30, 2016

2. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.

Roland R Griffiths, Matthew W Johnson1, Michael A Carducci, Annie Umbricht, William A Richards, Brian D Richards, Mary P Cosimano and Margaret A Klinedinst.

– September 6, 2010

3. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancerA; A double-blind, placebo-controlled study.

Charles S Grob, Alicia L Danforth, Gurpreet S Chopra, Marycie Hagerty, Charles R McKay, Adam L Halberstadt, George R Greer.

Let us tell you more.

We will email you to start the conversation.

accelerated access to safe and effective psychedelic-assisted therapy for patients with urgent, unmet needs.

Facebook
Twitter
Linkedin
Youtube
Envelope
  • Legal Disclaimer
  • Privacy Policy
  • Modern Slavery Statement
  • Cookie Policy
Menu
  • Legal Disclaimer
  • Privacy Policy
  • Modern Slavery Statement
  • Cookie Policy
  • About
  • Team
  • Clinical Studies
  • Investing
  • Press
  • Contact
Menu
  • About
  • Team
  • Clinical Studies
  • Investing
  • Press
  • Contact

© 2021 Albert Labs. All Rights Reserved

Canada – 6996, Merritt Ave, Burnaby, BC, V5J 4R6 | United kingdom – 21 Marylebone High St, Unit 6, Marylebone, London W1U 4PE

By completing this form you agree to our privacy policy. You will be sent corporate updates and further details including how to invest in Albert Labs.

By completing this form you agree to our privacy policy. You will be sent corporate updates and further details including how to invest in Albert Labs.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok